Treosulfan (Trecondi®) in combination with fludarabine [TRE1]
Treosulfan (Trecondi®) in combination with fludarabine for part of conditioning treatment prior to allogeneic haemopoietic stem cell transplantation malignant disease in ADULTS for whom reduced intensity conditioning regimen (such as low dose busulfan with fludarabine) would otherwise be suitable where the following criteria have been met: There is a separate form TRE2 for treosulfan in combination with fludarabine for part of conditioning treatment prior to allogeneic haemopoietic stem cell transplantation malignant disease in PAEDATRIC PATIENTS OLDER THAN 1 MONTH AND YOUNGER
- This application for treosulfan (as Trecondi®) in combination with fludarabine is being made by and will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy and who has specific expertise in the allogeneic stem cell transplantation of malignant disease. for a
- The patient is an adult and the allogeneic stem cell transplantation is for the treatment of malignant disease.
- This patient is ineligible for high intensity myeloablative therapy and as a consequence a reduced intensity conditioning regimen (such as low dose busulfan plus fludarabine or low dose melphalan plus fludarabine) as treatment prior to allogeneic stem cell transplantation would otherwise be suitable.
- Treosulfan (as Trecondi®) plus fludarabine will be used as part of the reduced intensity conditioning treatment prior to the allogeneic stem cell transplantation. for Note: Trecondi® is the only licensed formulation of tresosulfan for use in this indication.
- Treosulfan (as Trecondi®) and fludarabine (including their doses and schedules of administration) will be otherwise used as set out in their respective Summaries of Product Characteristics (SmPCs).
[NHS funded]{.badge .rounded-pill .bg-success} From: 03 November 2020
Additional information
Current Form Version
Important
This is an older version of the form. To view the most up to date form follow this link